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treatment.Fig 1. Livedoid vasculopathy presenting with ulcerations
on the left lower extremity (pre-treatment).INTRODUCTION
Livedoid vasculopathy is a disorder which is
thought to be caused by systemic dysregulation of
coagulation, resulting in the formation of fibrin
thrombi in the superficial dermal plexus. Chronic
disease often results in painful, punched out ulcer-
ations and atrophie blanche on the lower extrem-
ities, predisposing affected patients toward infection
and high morbidity. Treatment of livedoid vasculop-
athy is controversial and often ineffective. Owing
to the postulated pathophysiology, rivaroxaban
recently was suggested as a treatment modality and
seems to induce significant improvement in some
patients. Herein, we report the successful treatment
of recalcitrant livedoid vasculopathy in one patient
with no identifiable coagulopathy and propose that a
therapeutic trial of rivaroxaban may be helpful in
patients with no detectable underlying coagulability
disorders. Further evidence of clinical efficacy is
needed to confirm the benefit of rivaroxaban in
patients with livedoid vasculopathy.CASE REPORT
A 57-year-old woman presented to our clinic
shortly after a receiving a diagnosis of livedoid
vasculopathy. She had a 2.5-year history of painful,
violaceous, retiform macules and papules on the
bilateral lower extremities with ulcerations and
scarring (Fig 1). The diagnosis of livedoid vasculop-
athy was made based on the appearance of the
lesions, clinical history, and biopsy of a lesion from
the left ankle showing dilated vascular structures
with fibrin in the vessel wall, epidermal ulceration,
and hemorrhagic serum crust. The patient gave
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also had no known family history of lupus, clotting
disorders, or miscarriages. Numerous hypercoagula-
bility studies (Table I), cancer screenings, and
autoimmune tests found no abnormalities. Various
treatments reported to improve livedoid vasculop-
athy were tried with no improvement in pain or
physical findings. Cellulitis developed, which was
treated and resolved with intravenous and oral
antibiotics. She finally experienced mild improve-
ment on a regimen of nifedipine, 30 mg daily,
aspirin, 325 mg daily, and pentoxifylline, 400 mg 3
times daily. However, she acutely worsened after the
pentoxifylline was tapered to once daily, prompting
us to resume 3-times-daily dosing. Despite this
treatment regimen, she continued to have numerous
ulcerations with infections on her lower extremity,
including by Staphylococcus aureus, and had to be
hospitalized for treatment. Psoralen plus ultraviolet
light therapy was tried in between infectious epi-
sodes with no improvement.JAAD Case Reports 2015;1:340-1.
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Fig 2. Well-healed ulcers after 8 months of rivaroxaban.
Table I. Laboratory studies performed
Tests Results
Homocysteine level Normal
Protein C level Normal
Protein S level Normal
Anticardiolipin antibodies Negative
Lupus anticoagulant Negative
Beta-2 glycoprotein 1 antibodies Negative
Cryoglobulins Negative
Factor V Leiden mutation Negative
Prothrombin gene mutation (G20210A) Negative
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patient, we decided to initiate a trial of rivaroxaban at
20 mg daily. At her 2-month follow-up, the patient’s
pain had greatly improved, and many of her ulcer-
ations had resolved. No sign of infection was pre-
sent, and only residual scarring was noted on
physical examination. The improvement seen on
rivaroxaban was markedly better than that of any
previous treatment the patient had received and has
continued to be efficacious after 8 months of
treatment with complete healing of all previous
ulcers and no new ulcers (Fig 2).
DISCUSSION
Livedoid vasculopathy is a disease that generally
affects the lower extremities. Classically described in
young to middle-age women, livedoid vasculopathy
often presents as livedoid purpura with punched-out
ulcerations, often resulting in atrophie blanche.1 At
one time, atrophie blanche was considered synony-
mous for livedoid vasculopathy. However, by its
current usage, atrophie blancheelike lesions are not
specific to livedoid vasculopathy. For this reason and
because of a lack of consistent diagnostic criteria, the
literature on livedoid vasculopathy is often not clear.
Clinical differential diagnoses include other vasculardiseases such as antiphospholipid antibody syn-
drome or venous stasis disease. Therefore, a biopsy
may aid in arriving at the correct diagnosis.
Histopathology may show a mild perivascular lym-
phocytic infiltrate, hyalinization of small dermal
vessels, and intraluminal thromboses.2
Livedoid vasculopathy is seen in patients with and
without identifiable coagulation abnormalities.3
Accordingly, anticoagulation therapy is believed to
be helpful in at least some cases of livedoid
vasculopathy. Our patient had longstanding, intrac-
table livedoid vasculopathy complicated by recur-
rent skin infections. Despite a thorough coagulation
workup, she did not have any identifiable coagula-
tion abnormalities. Her favorable response to rivar-
oxaban, however, may suggest an occult coagulation
abnormality that portended a tendency toward live-
doid vasculopathy and remained undetected by
laboratory testing. Rivaroxaban has been described
in the treatment of livedoid vasculopathy.4 However,
there has been only one reported case of a patient
who was treated successfully with no known coa-
gulopathy.5 Our case also shows the potential utility
of rivaroxaban in the treatment of livedoid vascul-
opathy with no identifiable coagulation disorder.
Unfortunately, it is not possible to determine the role
of rivaroxaban in the treatment algorithm of livedoid
vasculopathy without a multicenter therapeutic trial.
An ongoing phase II multicenter trial is currently
assessing the efficacy of rivaroxaban in treating pain
in livedoid vasculopathy.6 Results from this trial are
not yet available. In our experience, we believe that
the current anecdotal evidence is sufficient to war-
rant a trial of rivaroxaban for patients with recalci-
trant livedoid vasculopathy, even in the absence of
known coagulopathy.
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